Dr Mette Tetsche and colleagues from Denmark examined whether acute pancreatitis is associated with the use of postmenopausal hormonal replacement therapy.
The team of doctors based this population-based case-control study on data from 3 Danish counties for the years 1991 to 2003.
|For current users of combined hormones, the relative risk was 1.1|
|American Journal of Gastroenterology|
The doctors identified 1054 women over 45 years of age with a first hospital discharge diagnosis of acute pancreatitis in the hospital discharge registries.
The team using the Danish Civil Registration System.
The doctors selected 10 age-matched population controls for each case, using risk set sampling.
The team collected data on all prescriptions for estrogens or combined estrogen with progestin redeemed within 90 days before the hospitalization.
Former users were defined as those collecting prescriptions from 91 and 365 days before hospitalization.
Conditional logistic regression was used to estimate the relative risk of acute pancreatitis after exposure to estrogen or combined estrogen with progestin.
The team adjusted for other risk factors for acute pancreatitis.
The doctors found that the adjusted relative risk for acute pancreatitis in current and former users of menopausal estrogens was 1.1.
For current users of combined estrogen with progestins, the adjusted relative risk was 1.2.
The team noted that for former users, the adjusted relative risk was 1.6.
Dr Tetsche's team comments, “The data did not support a substantial association between acute pancreatitis and the use of postmenopausal hormone therapy.”